Doxorubicin/taxane combinations: Cardiac toxicity and pharmacokinetics

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Doxorubicin and the taxanes, paclitaxel and docetaxel (Taxotere; Rhone- Poulenc Rorer, Collegeville, PA), are among the most active cytotoxic agents for the treatment of metastatic breast cancer. Given their activity, relative non-cross-resistance, partially non-overlapping toxicities, and differing mechanisms of action, there is a clear rationale for combining these agents for both advanced and early stage disease. Phase I and II trials have been reported for both doxorubicin/paclitaxel and doxorubicin/docetaxel. Response rates have been generally high for both combinations. Some groups have reported an unacceptably high risk of congestive heart failure in patients treated with some schedules of doxorubicin/paclitaxel if the cumulative doxorubicin dose exceeded 360 mg/m2. A similar effect has not been observed with doxorubicin/docetaxel combinations. This is likely explained by a pharmacokinetic interference of doxorubicin elimination by paclitaxel, an effect that is highly dependent on the interval between administration of the drugs and the duration of the paclitaxel drug infusion. Such an interaction has not been observed with doxorubicin/docetaxel, providing an explanation for the lack of enhanced cardiotoxicity with docetaxel-containing combination. Phase III trials comparing doxorubicin/taxane combinations with standard regimens have been completed and are in progress, and should help define whether the use of these drugs in combination offers any advantage over their use in a sequential fashion in both early and advanced disease.

Original languageEnglish (US)
Pages (from-to)14-19
Number of pages6
JournalSeminars in Oncology
Volume26
Issue number3 SUPPL. 9
StatePublished - 1999

Fingerprint

docetaxel
Doxorubicin
Pharmacokinetics
Paclitaxel
Cardiotoxicity
taxane
Taxoids
Cytotoxins
Drug Combinations
Pharmaceutical Preparations
Appointments and Schedules
Heart Failure
Breast Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Doxorubicin/taxane combinations : Cardiac toxicity and pharmacokinetics. / Sparano, Joseph A.

In: Seminars in Oncology, Vol. 26, No. 3 SUPPL. 9, 1999, p. 14-19.

Research output: Contribution to journalArticle

@article{5b13cacae2ea46deaff47bb54d38ebd8,
title = "Doxorubicin/taxane combinations: Cardiac toxicity and pharmacokinetics",
abstract = "Doxorubicin and the taxanes, paclitaxel and docetaxel (Taxotere; Rhone- Poulenc Rorer, Collegeville, PA), are among the most active cytotoxic agents for the treatment of metastatic breast cancer. Given their activity, relative non-cross-resistance, partially non-overlapping toxicities, and differing mechanisms of action, there is a clear rationale for combining these agents for both advanced and early stage disease. Phase I and II trials have been reported for both doxorubicin/paclitaxel and doxorubicin/docetaxel. Response rates have been generally high for both combinations. Some groups have reported an unacceptably high risk of congestive heart failure in patients treated with some schedules of doxorubicin/paclitaxel if the cumulative doxorubicin dose exceeded 360 mg/m2. A similar effect has not been observed with doxorubicin/docetaxel combinations. This is likely explained by a pharmacokinetic interference of doxorubicin elimination by paclitaxel, an effect that is highly dependent on the interval between administration of the drugs and the duration of the paclitaxel drug infusion. Such an interaction has not been observed with doxorubicin/docetaxel, providing an explanation for the lack of enhanced cardiotoxicity with docetaxel-containing combination. Phase III trials comparing doxorubicin/taxane combinations with standard regimens have been completed and are in progress, and should help define whether the use of these drugs in combination offers any advantage over their use in a sequential fashion in both early and advanced disease.",
author = "Sparano, {Joseph A.}",
year = "1999",
language = "English (US)",
volume = "26",
pages = "14--19",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 9",

}

TY - JOUR

T1 - Doxorubicin/taxane combinations

T2 - Cardiac toxicity and pharmacokinetics

AU - Sparano, Joseph A.

PY - 1999

Y1 - 1999

N2 - Doxorubicin and the taxanes, paclitaxel and docetaxel (Taxotere; Rhone- Poulenc Rorer, Collegeville, PA), are among the most active cytotoxic agents for the treatment of metastatic breast cancer. Given their activity, relative non-cross-resistance, partially non-overlapping toxicities, and differing mechanisms of action, there is a clear rationale for combining these agents for both advanced and early stage disease. Phase I and II trials have been reported for both doxorubicin/paclitaxel and doxorubicin/docetaxel. Response rates have been generally high for both combinations. Some groups have reported an unacceptably high risk of congestive heart failure in patients treated with some schedules of doxorubicin/paclitaxel if the cumulative doxorubicin dose exceeded 360 mg/m2. A similar effect has not been observed with doxorubicin/docetaxel combinations. This is likely explained by a pharmacokinetic interference of doxorubicin elimination by paclitaxel, an effect that is highly dependent on the interval between administration of the drugs and the duration of the paclitaxel drug infusion. Such an interaction has not been observed with doxorubicin/docetaxel, providing an explanation for the lack of enhanced cardiotoxicity with docetaxel-containing combination. Phase III trials comparing doxorubicin/taxane combinations with standard regimens have been completed and are in progress, and should help define whether the use of these drugs in combination offers any advantage over their use in a sequential fashion in both early and advanced disease.

AB - Doxorubicin and the taxanes, paclitaxel and docetaxel (Taxotere; Rhone- Poulenc Rorer, Collegeville, PA), are among the most active cytotoxic agents for the treatment of metastatic breast cancer. Given their activity, relative non-cross-resistance, partially non-overlapping toxicities, and differing mechanisms of action, there is a clear rationale for combining these agents for both advanced and early stage disease. Phase I and II trials have been reported for both doxorubicin/paclitaxel and doxorubicin/docetaxel. Response rates have been generally high for both combinations. Some groups have reported an unacceptably high risk of congestive heart failure in patients treated with some schedules of doxorubicin/paclitaxel if the cumulative doxorubicin dose exceeded 360 mg/m2. A similar effect has not been observed with doxorubicin/docetaxel combinations. This is likely explained by a pharmacokinetic interference of doxorubicin elimination by paclitaxel, an effect that is highly dependent on the interval between administration of the drugs and the duration of the paclitaxel drug infusion. Such an interaction has not been observed with doxorubicin/docetaxel, providing an explanation for the lack of enhanced cardiotoxicity with docetaxel-containing combination. Phase III trials comparing doxorubicin/taxane combinations with standard regimens have been completed and are in progress, and should help define whether the use of these drugs in combination offers any advantage over their use in a sequential fashion in both early and advanced disease.

UR - http://www.scopus.com/inward/record.url?scp=0032790047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032790047&partnerID=8YFLogxK

M3 - Article

C2 - 10426454

AN - SCOPUS:0032790047

VL - 26

SP - 14

EP - 19

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 9

ER -